Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg990, Its Novel Half-Life Extended Ox40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Apogee Therapeutics宣佈Apg990的第一批參與者接受了治療，並開展了第一階段的臨床試驗。Apg990是一種新型的半衰期延長的Ox40L抗體，用於治療特應性皮炎和其他炎症性疾病。